Setting up a one stop shop PETCT and ceCT service for management of patients with lymphoma
Hybrid imaging is an integral part of nuclear medicine services. The possibility to combine morphologic and functional data has changed patient pathways and had a major impact in the diagnosis and management of oncology patients. CT using contrast enhancement (ceCT) is an important tool to monitor anatomical change. However, with lymphoma imaging, delineation of pathologic changes in normal sized lymph nodes or extra-nodal disease may be a limitation of CT. 18F-Fluorodeoxyglucose (FDG) PET is useful for staging lymphoma but has issues in terms of specificity due to the physiologic distribution of the tracer and also accumulation in sites of active inflammation and infection. These limitations could be overcome by combining ceCT and PETCT to produce accurate morphologic and functional images acquired on the same scanner. This is feasible as modern PETCT scanners have fully diagnostic CT systems.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.